Latest Regulatory Approvals News

29Metals delivered a robust December quarter at its Golden Grove mine with strong copper and zinc production, while Capricorn Copper remains suspended pending critical regulatory approvals. The company is progressing key growth projects and board changes as it navigates liquidity and operational challenges.

29Metals reported a strong December quarter with increased copper and zinc production at Golden Grove, cost efficiencies, and steady progress on key projects, while Capricorn Copper remains suspended pending regulatory approvals.

HUB24 has reported record net inflows of $5.6 billion in Q2 FY26, pushing total funds under administration to $152.3 billion and expanding its market share to 9.3%. The company also unveiled a new lifetime retirement solution and an AI-driven adviser ecosystem.

Hot Chili Limited reports significant diamond drilling results at its La Verde copper-gold project in Chile, revealing extensive high-grade mineralisation from near surface and extending previous intercepts. These findings bolster the strategic value of the Costa Fuego project amid rising copper and gold prices.

Tungsten Mining NL advances its Mt Mulgine project with a robust scoping study, revealing a globally significant multi-critical mineral deposit poised to meet soaring tungsten demand amid supply constraints.

Fletcher Building has agreed to sell its Construction Division to global giant VINCI Construction for an initial $315.6 million, with potential to rise to $334.1 million. The move marks a strategic pivot towards focused building products manufacturing.

AuKing Mining reports promising exploration results at Myoff Creek and steady progress at Koongie Park, while grappling with a failed Cloncurry acquisition and significant board changes.

Arena REIT has announced an ordinary quarterly dividend of AUD 0.048125 per security, payable on 5 February 2026, alongside a Dividend Reinvestment Plan priced at AUD 3.50330, offering investors a 1.5% discount.

Mesoblast has received encouraging feedback from the FDA on its cell therapy rexlemestrocel-L, showing meaningful pain relief and potential opioid use reduction in chronic low back pain patients. The company’s ongoing Phase 3 trial aims to confirm these benefits and advance regulatory approval.

Nickel Industries faced a challenging December quarter due to delayed regulatory approvals impacting ore sales, yet the company kicked off 2026 with robust nickel ore sales and record earnings from its HPAL project.

Riversgold Limited reports encouraging shallow gold intersections at its Northern Zone Gold Project near Kalgoorlie, supported by a $2.15 million capital raise with MEGA Resources as a key investor. The drilling results and strategic partnership set the stage for advancing mining plans in 2026.

Neuren Pharmaceuticals has affirmed the material impact of Acadia’s projection that DAYBUE global net sales could reach approximately US$700 million by 2028, underpinning its royalty revenue outlook.